CPR Invest - Smart Trends - A EUR - Acc ISIN : LU1989771529
NAVs
Performance
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
Portfolio Analysis
Sector | Weight | |
|---|---|---|
| ARI - EUROPEAN CREDIT- I2 - C | Investment Grade EMU | 18.60% |
| Amundi EUR Corporate Bond ESG ETF DR C | Investment Grade EMU | 15.36% |
| CPR INVEST - CLIMATE BONDS EURO - Z EUR | Investment Grade EMU | 15.12% |
| AM EURO LIQUIDITY S-T RESP - Z (C) | Money Market Investments | 12.77% |
| AMUN EUR HY Corp Bd ESG UCITS Dist (PAR) | High Yield Europe | 8.16% |
| CPR INV B&W EU STRAT AUTO 2028 II | Investment Grade Europe | 6.06% |
| Amundi USD Corporate Bond ESG ETF DR C | Investment Grade USA | 5.85% |
| Amundi IS USD Emerg Mkts Govt Bd ETF Acc | Govies Emerging Global | 5.05% |
| CPR INVEST AI O EUR C | Equities World | 1.97% |
| WisdomTree BioRevolution ETF - USD Acc | Equities World | 1.64% |
Management commentary
The month of October 2026 was marked by a new surge in energy prices. Indeed, attacks on ships continued in the Strait of Hormuz, the Houthis claimed responsibility for strikes against several Saudi refineries, and Donald Trump hinted that US strikes on Iran could resume after the midterm elections on November 3. As a result, the price of Brent crude rose by nearly 14% over the month, reaching $118, its highest level in six months. The price of natural gas also increased sharply, reaching its highest level since the end of 2022. Another key event of the month was the sharp decline in technology stocks at the very end of the month, following disappointing earnings reports from Alphabet, Amazon, and Intel, which reignited doubts about the profitability of massive investments in AI.
Inflation indices published in October, covering the month of September, accelerated again due to energy prices. In the eurozone, headline inflation reached 3.8% compared to 3.2% in August, its highest level since September 2023, with the energy component rising by 18.8% year-on-year. In contrast, core inflation remained broadly stable at 2.5%. In the United States, headline inflation (CPI) rose from 3.4% to 3.7%, while core inflation climbed to 2.6%, slightly more than expected. The September “core PCE” inflation came in at 3.1%.
Activity indicators continued to be robust. In the United States, Q3 GDP growth came in at 3.4% quarter-on-quarter annualized, above expectations, driven by consumer spending and business investment. However, after a strong report in August, the September employment report disappointed, with only 29,000 non-farm jobs created and an increase in the unemployment rate to 4.2%. In the eurozone, GDP grew by 0.4% in Q3, despite a surprise 0.1% contraction in France, but the composite PMI fell to 51.9 in October from 53.1 in September, well below expectations. In China, GDP growth came in at 4.5% year-on-year in Q3, but the economy remains highly unbalanced and household consumption very weak.
After September, the first month in history during which the ECB, the Fed, and the BoJ all raised their key rates, these three central banks all decided to leave their rates unchanged in October. The Fed maintained the fed funds target range at 3.75/4%, but two FOMC members (Lisa Cook and Beth Hammack) voted in favor of another hike. Kevin Warsh indicated that the September rate hike had begun to take effect and that the tightening of financial conditions was paving the way for a period of more sustainable growth and price stability. For its part, the BoJ left its main policy rate at 1.25% but opened the door to a hike in December. Finally, the ECB left its deposit rate at 2.50%, even though energy prices in Europe are now between the “adverse” and “severe” scenarios mentioned in September, fueling upside risks for inflation and downside risks for growth. The Council debated a new rate hike but judged that uncertainties were still too high, while indicating that “the direction is quite clear” for all its members. For now, it does not see a substantial risk of second-round effects.
Despite the rise in oil prices, bond yields fell sharply over the month, benefiting from a flight to safe-haven assets at the end of the month and the central banks’ pause. The US 10-year yield fell by nearly 40 bps to 4.90%, after briefly exceeding 5.30% during the month. The German 10-year yield fell by about 25 bps over the month to 3.29%, returning to its end-August levels. In Japan, the 10-year yield fell back below the 3% mark, to 2.77%, its lowest level in nearly three months. Finally, gold fell again, by about 6% over the month, to just over $3,875 an ounce, penalized by the prospect of further Fed rate hikes.
Equity markets were shaken at the end of the month by doubts about the profitability of AI-related investments. The S&P 500 fell by 0.9% over the month and the Nasdaq by more than 5%, while the Dow Jones rose by 1.7%. The Eurostoxx 600 was more resilient, with an increase of 1.9%. Asian markets, more exposed to the semiconductor sector, fell sharply: the Nikkei lost nearly 5.2% and the MSCI Emerging dropped 8.1%, its worst month since the start of the war in Iran.
On the thematic side, after several months dominated by large technology stocks and artificial intelligence, investors began to favor defensive sectors, undervalued stocks, and quality assets. The correction in AI-related stocks does not necessarily signal the end of the technology cycle, but rather reflects a heightened demand for profitability and financial discipline.
Investors are now questioning: the very high level of investment in AI infrastructure, the ability of hyperscalers to turn these investments into cash flow, the future profitability of data centers, and the debt levels of certain cloud specialists. The question is no longer just who will benefit from AI, but above all who will be able to sustainably capture its economic value.
October 2026 confirmed the role of the healthcare sector as a safe haven, and AI-driven drug discovery is emerging as a new strong thematic focus. The main challenge for investors lies in balancing the undeniable acceleration of drug discovery by AI and its still uncertain impact on clinical success—a distinction that is increasingly influencing stock selection within this sector.
Around consumer themes, quarterly reports showed that the preference for experiences over goods has intensified, with high-end travel and beauty remaining strong segments, while non-essential retail—particularly in China and among low-income households globally—faced significant challenges. This K-shaped dynamic is the guiding thread for consumer brand positioning, favoring premium, good value-for-money, and experience-focused brands over mid-range and luxury brands.
In October, CPR Smart Trends was down 0.18%. Equity exposure was reduced over the month from 18.5% to 13.5%. In terms of equity bets, we significantly reduced our exposure to the AI theme and increased our position in Healthcare. For the rates segment, following the “flight to quality” observed during the month, we increased our rate sensitivity by 40bps to 3.65.
Characteristics
General data
Costs Composition
| One-off costs upon entry or exit (Investment EUR 10,000) | If you exit after 1 year | ||
| Entry costs | This includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge. | Up to €500.00 | |
| Exit costs | We do not charge an exit fee for this product, but the person selling you the product may do so. | €0.00 | |
| Ongoing costs taken each year (Investment EUR 10,000) | |||
| Management fees and other administrative or operating costs | 1.28% of the value of your investment per year. This percentage is based on actual costs over the last year. | €121.79 | |
| Transaction costs | 0.13% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell. | €12.57 | |
| Incidental costs taken under specific conditions (Investment EUR 10,000) | |||
| Performance fees | 15.00% annual outperformance of the reference asset 100% ESTR CAPITALISE (OIS). The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years. The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset. | €0.00 | |
Codification
Investment Objective
Documents
| Language | Documents | Type | Closing Date |
|---|---|---|---|
CS | PDF | 04/11/2026 | |
PDF | 01/10/2026 | ||
EN | PDF | 31/07/2025 | |
PDF | 31/01/2026 | ||
CS | PDF | 31/10/2026 | |
EN | PDF | 26/10/2016 |
Sustainability-related disclosures
| Language | Documents | Type | Closing Date |
|---|---|---|---|
CS | PDF | 01/01/2025 | |
EN | PDF | 03/08/2026 |
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.